scholarly journals Nutrition and Rheumatoid Arthritis in the ‘Omics’ Era

Nutrients ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 763
Author(s):  
Manuela Cassotta ◽  
Tamara Y. Forbes-Hernandez ◽  
Danila Cianciosi ◽  
Maria Elexpuru Zabaleta ◽  
Sandra Sumalla Cano ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Autoimmune Disease ◽  
Environmental Factors ◽  
Nutritional Factors ◽  
Omics Technologies ◽  
Food Components ◽  
Nutritional Advice ◽  
The Individual ◽  
Chronic Autoimmune Disease ◽  
Nutritional Sciences

Modern high-throughput ‘omics’ science tools (including genomics, transcriptomics, proteomics, metabolomics and microbiomics) are currently being applied to nutritional sciences to unravel the fundamental processes of health effects ascribed to particular nutrients in humans and to contribute to more precise nutritional advice. Diet and food components are key environmental factors that interact with the genome, transcriptome, proteome, metabolome and the microbiota, and this life-long interplay defines health and diseases state of the individual. Rheumatoid arthritis (RA) is a chronic autoimmune disease featured by a systemic immune-inflammatory response, in genetically susceptible individuals exposed to environmental triggers, including diet. In recent years increasing evidences suggested that nutritional factors and gut microbiome have a central role in RA risk and progression. The aim of this review is to summarize the main and most recent applications of ‘omics’ technologies in human nutrition and in RA research, examining the possible influences of some nutrients and nutritional patterns on RA pathogenesis, following a nutrigenomics approach. The opportunities and challenges of novel ‘omics technologies’ in the exploration of new avenues in RA and nutritional research to prevent and manage RA will be also discussed.

scholarly journals Gambaran Pasien Reumatoid Artritis di RSUD Arifin Achmad Riau Province 2015 - 2019

2021 ◽  
Vol 14 (1) ◽  
pp. 45
Author(s):  
Jelita Sri Agustin ◽  
Huriatul Masdar ◽  
Asrizal Asrizal
Keyword(s):  
Rheumatoid Arthritis ◽  
Autoimmune Disease ◽  
Joint Pain ◽  
Pharmacological Therapy ◽  
Age Group ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Erythrocyte Sedimentation ◽  
Laboratory Examinations ◽  
Chronic Autoimmune Disease

Rheumatoid Arthritis (RA) is a chronic autoimmune disease that causes tissue damage, deformity, and death if not treated immediately. The aim of this study  to description of RA patients in the Regional General Hospital (RSUD) Arifin Achmad Riau Province 2015 – 2019. The results showed that total cases was 55 cases with the more common in female (87,3%) with most age group was 46-55 years (34,5%) and the main complaints were joint pain (85,5%). Rheumatoid arthritis patients with laboratory examinations were non-reactive rheumatoid factor (RF) levels by 20 patients out of 30 patients, levels of Anti-Citrullinated Protei  Antibodies (ACPA) or Immunoglobulin G anti-Cyclic Citrulinated Protein (IgG anti-CCP) reactive by 3 patients out of 4 patients, levels C-Reactive Protein (CRP) abnormal by 18 patients out of 21 patients and levels Erythrocyte Sedimentation Rate (ESR) abnormal by 20 patients out of 23 patients. The results also showed that the most pharmacological therapy given was corticosteroid (87,3%)

Gut microbiota mediated the protective effects of tuna oil on collagen-induced arthritis in mice

2021 ◽  
Author(s):  
Chenyang Lu ◽  
Ju Chen ◽  
Congmin Yi ◽  
Jiaojiao Han ◽  
Qiuyue Shi ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Autoimmune Disease ◽  
Gut Microbiota ◽  
Protective Effects ◽  
Collagen Induced Arthritis ◽  
Tuna Oil ◽  
Beneficial Effects ◽  
Chronic Autoimmune Disease

Rheumatoid arthritis is emerging as a chronic autoimmune disease worldwide. In this study, the components of tuna oil (TO) were firstly measured, and the beneficial effects of TO on collagen-induced...

scholarly journals Proportion and Factors that Associate with Incidence of Hepatotoxicity in Rheumatoid Arthritis Patients Treated with Methotrexate in RSCM Year 2013−2015

2018 ◽  
Vol 10 (1) ◽  
Author(s):  
Rahma Anindya Prathitasari ◽  
Harry Isbagio
Keyword(s):  
Quality Of Life ◽  
Rheumatoid Arthritis ◽  
Autoimmune Disease ◽  
Aspartate Aminotransferase ◽  
Alanine Aminotransferase ◽  
Side Effect ◽  
Normal Limit ◽  
Keywords Rheumatoid Arthritis ◽  
Chronic Autoimmune Disease

Background Rheumatoid arhtirtis (RA) is a chronic autoimmune disease that mainly attacks joints. It may causes joint deformities which leads to lower quality of life of RA patients. RA is treated with metothrexate (MTX) which inhibiting disease progression. MTX is known for its hepatotoxicity side effect, which is described by an elevation of aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) beyond the upper normal limit. Factors that may enhance hepatotoxicity are gender, age, cummulative dose of MTX, and duration therapy of MTX. Prevalence of hepatotoxicity caused by MTX therapy in RA patients in Indonesia is still unknown. The objective of this research is to know the proportion of hepatotoxicity and its associations with the factors that may enhance hepatotoxicity caused by MTX therapy in RA patients in RSCM.Method Data about gender, age, cummulative dose and duration therapy of MTX are obtained from 115 RA patients' medical records.Result Proportion of hepatotoxicity in RA patients treated with MTX in RSCM is 42.60%. Gender, age, cummulative dose and duration therapy of MTX do not significantly enhance hepatotoxicity (p>0.05).Conclusion In conclusion gender, age, cummulative dose and duration therapy of MTX do not have association with hepatotoxicity in RA patients treated with MTX. Keywords: Rheumatoid Arthritis, Methotrexate, Hepatotoxicity

scholarly journals LncRNA: An all-rounder in rheumatoid arthritis

2019 ◽  
Vol 7 (1) ◽  
pp. 3-9 ◽  
Author(s):  
Junyu Liang ◽  
Weiqian Chen ◽  
Jin Lin
Keyword(s):  
Rheumatoid Arthritis ◽  
Autoimmune Disease ◽  
Disease Activity ◽  
Therapeutic Targets ◽  
Non Coding Rnas ◽  
Chronic Autoimmune Disease

Abstract Rheumatoid arthritis (RA) is a chronic autoimmune disease and is supposed to have both genetic and environmental backgrounds. Plenty of studies have demonstrated the roles of long non-coding RNAs (lncRNAs) in the initiation and development of RA. Numerous lncRNAs have been found to be dysregulated in RA and to be correlated with disease activity of RA, which indicates potential diagnostic roles of lncRNAs. In addition to working as biomarkers for RA, lncRNAs participate in many specific pathological processes including inflammation, aberrant proliferation, migration, invasion and apoptosis. Further screenings and researches are required to validate the clinical potentials of lncRNAs as diagnostic and therapeutic targets in RA.

Autoantibodies in rheumatoid arthritis

2020 ◽  
pp. 65-72
Author(s):  
Tom W.J. Huizinga
Keyword(s):  
Rheumatoid Arthritis ◽  
Risk Factors ◽  
Autoimmune Disease ◽  
Characteristic Feature ◽  
Pathogenic Potential ◽  
Pathogenetic Role ◽  
Autoantibody Response ◽  
Chronic Autoimmune Disease ◽  
Underlying Pathophysiology

Autoantibodies are a characteristic feature of autoimmune diseases. Although the exact pathogenetic role of autoantibodies is in general not known, they are very often useful for diagnostic purposes. Rheumatoid arthritis (RA) is a chronic autoimmune disease primarily affecting the joints. RA is a heterogeneous disease that encompasses several disease subsets with probable differences in underlying pathophysiology. Via a final common inflammatory pathway these different pathophysiological pathways might lead to a similar clinical presentation of arthritis. The best-known subdivision in RA is between autoantibody positive and autoantibody negative RA, which differ in both risk factors and clinical outcomes. This chapter focuses on the role of autoantibodies in the pathophysiology of RA. First, the relation between autoantibodies and known risk factors for RA will be discussed. Thereafter, the specific characteristics of the autoantibody response and the pathogenic potential of the different autoantibodies are reviewed.

scholarly journals Application of nanomaterials in the treatment of rheumatoid arthritis

RSC Advances ◽  
2021 ◽  
Vol 11 (13) ◽  
pp. 7129-7137
Author(s):  
Miaomiao Zheng ◽  
Huiju Jia ◽  
Huangwei Wang ◽  
Linhong Liu ◽  
Zhesheng He ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Autoimmune Disease ◽  
Bone Tissue ◽  
Synovial Joints ◽  
Chronic Autoimmune Disease

Rheumatoid Arthritis (RA) is a chronic autoimmune disease, which mainly causes inflammation of the synovial joints and destruction of cartilage and bone tissue.

scholarly journals Proportion and Factors that Associate with Incidence of Hepatotoxicity in Rheumatoid Arthritis Patients Treated with Methotrexate in RSCM Year 2013−2015

2018 ◽  
Vol 10 (1) ◽  
Author(s):  
Rahma Anindya Prathitasari ◽  
Harry Isbagio
Keyword(s):  
Quality Of Life ◽  
Rheumatoid Arthritis ◽  
Autoimmune Disease ◽  
Disease Progression ◽  
Alanine Aminotransferase ◽  
Side Effect ◽  
Normal Limit ◽  
Keywords Rheumatoid Arthritis ◽  
Chronic Autoimmune Disease

Background Rheumatoid arhtirtis (RA) is a chronic autoimmune disease that mainly attacks joints. It may causes joint deformities which leads to lower quality of life of RA patients. RA is treated with metothrexate (MTX) which inhibiting disease progression. MTX is known for its hepatotoxicity side effect, which is described by an elevation of aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) beyond the upper normal limit. Factors that may enhance hepatotoxicity are gender, age, cummulative dose of MTX, and duration therapy of MTX. Prevalence of hepatotoxicity caused by MTX therapy in RA patients in Indonesia is still unknown. The objective of this research is to know the proportion of hepatotoxicity and its associations with the factors that may enhance hepatotoxicity caused by MTX therapy in RA patients in RSCM.Method Data about gender, age, cummulative dose and duration therapy of MTX are obtained from 115 RA patients' medical records.Result Proportion of hepatotoxicity in RA patients treated with MTX in RSCM is 42.60%. Gender, age, cummulative dose and duration therapy of MTX do not significantly enhance hepatotoxicity (p>0.05).Conclusion In conclusion gender, age, cummulative dose and duration therapy of MTX do not have association with hepatotoxicity in RA patients treated with MTX. Keywords: Rheumatoid Arthritis, Methotrexate, Hepatotoxicity

Polypeptide nano-Se targeting inflammation and theranostic rheumatoid arthritis by anti-angiogenic and NO activating AMPKα signaling pathway

2018 ◽  
Vol 6 (21) ◽  
pp. 3497-3514 ◽  
Author(s):  
Yanan Liu ◽  
Litao Ma ◽  
Hui Zhou ◽  
Xufeng Zhu ◽  
Qianqian Yu ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Autoimmune Disease ◽  
Signaling Pathway ◽  
Chronic Autoimmune Disease ◽  
Effective Treatments

Rheumatoid arthritis (RA) is a chronic autoimmune disease and there is a lack of effective treatments.

Relationship of HLA-DRB1 Alleles and Rheumatoid Arthritis in West South of Iran

2017 ◽  
Vol 9 (03) ◽  
Author(s):  
Karim Mowla ◽  
Elham Rajaee M. D. ◽  
Mehrdad Dargahi-MalAmir M. D. ◽  
Neda Yousefinezhad ◽  
Maryam Jamali Hondori
Keyword(s):  
Rheumatoid Arthritis ◽  
Environmental Factors ◽  
Rheumatoid Factor ◽  
Dna Extraction ◽  
Wrist Joint ◽  
Blood Sampling ◽  
Healthy Controls ◽  
Relationship Of ◽  
Synovial Pannus

Background: Rheumatoid arthritis is a systemic multifactor disease that presented with symmetrical polyarthritis more preferably in small wrist joint and ankle. Synovial pannus cause destruction and deformities in joints. The main reason of this disease in unknown, but past researchesshowed that genetically factor play important role beside environmental factors in susceptibility to this entity. Method:100 patients with rheumatoid arthritis diagnosed upon ACR 2010 criteria enrolled study. 92 healthy patents also enrolled DNA studying. of both group was extracted through DNA extraction kits by blood sampling. HLA-DRB1 typing was done by PCR-SSP method. Results: There were no significant differences in HLADRB1 *04, HLADRB1*08 and HLADRB1*11 alleles presentation between patients and healthy controls. Only there were statically significant correlation between HLA-DRB1*08 and Rheumatoid factor positive patents. (P = 0.025).

Novel Nano Carriers for the Treatment of Progressive Auto Immune Disease Rheumatoid Arthritis

2020 ◽  
Vol 26 ◽  
Author(s):  
Ritu Mishra ◽  
Swati Gupta
Keyword(s):  
Rheumatoid Arthritis ◽  
Drug Delivery ◽  
Autoimmune Disease ◽  
Drug Delivery Systems ◽  
Clinical Manifestations ◽  
Adaptive Immune Response ◽  
Delivery Systems ◽  
Current Therapy ◽  
Genetic And Environmental Factors ◽  
Novel Drug

Background: Rheumatoid arthritis (RA) is the most common occurring progressive, autoimmune disease, affecting 1% of the population and the ratio of affected women is three times as compared to men in most developing countries. Clinical manifestations of RA are the presence of anti-citrullinated protein antibody (ACPA) and rheumatoid factor (RF) in blood, tendered joints and soreness of the muscles. Some other factors which may lead to chronic inflammation are genetic and environmental factors as well as adaptive immune response. Several conventional drugs are available for the treatment of RA but have their own drawbacks which can be overcome by the use of novel drug delivery systems. : The objective of the present review is to focus on the molecular pathogenesis of the disease and its current conventional treatment with special reference to the role of novel drug delivery systems encapsulating anti rheumatic drugs and herbal drugs in passive and receptor mediated active targeting against RA. On reviewing the conventional and current therapeutics agains RA, we conclude that, although the current therapy for the treatment of RA is capable enough, yet more advances in the field of targeted drug delivery will sanguinely result in effective and appropriate treatment of this autoimmune disease.

Sign in / Sign up

Export Citation Format

Share Document